AVEO Pharmaceuticals, Inc. (AVEO)

[pfelgueiras]

AVEO Pharma (AVEO)
smarteranalyst.com

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AVEO Pharma, with a price target of $9. The company’s shares closed yesterday at $2.54.

Ramakanth wrote:

“We maintain our Buy rating on AVEO and raise our 12- month price target to $9.00 per share, up from $6.50. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate.”

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.2% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.

Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $6.33, a 149.2% upside from current levels. In a report issued on October 22, Piper Jaffray also reiterated a Buy rating on the stock with a $5 price target.